Associated Papers
Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions.
Wong AKQ et al.
Current Oncology (toronto, Ont.), 2026
DNA polymerase epsilon-mutant colorectal cancers: Insights into non-exonuclease domain mutation variants, microsatellite instability status, and co-mutation profiles.
Taskiran I et al.
World Journal of Gastroenterology, 2025
Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.
Sun F et al.
Lung Cancer (amsterdam, Netherlands), 2025
Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations-An In Vitro Study.
Oiki H et al.
Cells, 2025
Saturation profiling of drug-resistant genetic variants using prime editing.
Kim Y et al.
Nature Biotechnology, 2025
Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing.
Mamesaya N et al.
International Journal of Clinical Oncology, 2025
Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945.
Wang Y et al.
Npj Precision Oncology, 2025
Genetic mechanisms of resistance to targeted KRAS inhibition.
Diaz BJ et al.
Biorxiv : the Preprint Server for Biology, 2025
An in-depth exploration of four heterogeneity structure-based EGFR mutation subgroups in Chinese non-small cell lung cancer.
Yu Y et al.
Bmc Pulmonary Medicine, 2025
Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fraction.
Sisoudiya SD et al.
Npj Precision Oncology, 2025
Prevalence and breakdown of KRAS driver mutations in a large UK non-small cell lung cancer cohort.
Niesner ICC et al.
Journal of Clinical Pathology, 2025
Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impact.
Huebner H et al.
Precision Clinical Medicine, 2025
Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations.
Piha-Paul SA et al.
Esmo Open, 2025
Genomic Landscape of Advanced Solid Tumors in Middle East and North Africa Using Circulating Tumor DNA in Routine Clinical Practice.
Dawood S et al.
Oncology, 2025
A Novel EGFR Germline Mutation in Lung Adenocarcinoma: Case Report and Literature Review.
Sharma P et al.
Clinical Lung Cancer, 2024
Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.
Hayes TK et al.
Nature Communications, 2024
Follicular cell-derived thyroid carcinomas harboring novel genetic BRAFNON-V600E mutations: real-world data obtained using a multigene panel.
von Ammon JL et al.
Archives of Endocrinology and Metabolism, 2024
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity.
Wei Y et al.
Molecular Oncology, 2023
Targeted molecular profiling of solid tumours-Indian tertiary cancer centre experience.
Gurav M et al.
Journal of Cancer Research and Clinical Oncology, 2023
Glioblastoma with novel EGFR mutations (T790M and exon 20 insertion) yet unresponsive to osimertinib: A case report.
Boongird A et al.
Genes, Chromosomes & Cancer, 2023
Germline EGFR mutations in lung cancer (Review).
Liu M et al.
Oncology Letters, 2023
Extreme Gradient Boosting Tuned with Metaheuristic Algorithms for Predicting Myeloid NGS Onco-Somatic Variant Pathogenicity.
Pellegrino E et al.
Bioengineering (basel, Switzerland), 2023
Pan-cancer molecular analysis of EGFR large fragment deletion in the Asian population.
Pu J et al.
Cancer Medicine, 2023
The Unique Genetic Mutation Characteristics Based on Large Panel Next-Generation Sequencing (NGS) Detection in Multiple Primary Lung Cancers (MPLC) Patients.
Liang Z et al.
Discovery Medicine, 2023
Assessment of the Mutation Profile of Tonsillar Squamous Cell Carcinomas Using Targeted Next-Generation Sequencing.
Park HY et al.
Biomedicines, 2023
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea.
Ahn BC et al.
Cancer Treatment and Research Communications, 2023
Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer.
Zhang L et al.
Molecular Oncology, 2022
Structure-based classification of EGFR mutations in operable pre-invasive and invasive non-small cell lung cancer: a cross-sectional study.
Wang T et al.
Journal of Thoracic Disease, 2022
Base editing sensor libraries for high-throughput engineering and functional analysis of cancer-associated single nucleotide variants.
Sánchez-Rivera FJ et al.
Nature Biotechnology, 2022
Unique characteristics of G719X and S768I compound double mutations of epidermal growth factor receptor (EGFR) gene in lung cancer of coal-producing areas of East Yunnan in Southwestern China.
Wang JL et al.
Genes and Environment : the Official Journal of the Japanese Environmental Mutagen Society, 2022
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.
Cho BC et al.
Current Oncology (toronto, Ont.), 2022
Investigation of the prevalence and clinical implications of ERBB2 exon 16 skipping mutations in Chinese pan-cancer patients.
Shang Y et al.
Frontiers in Oncology, 2022
Pediatric Gliomas Presenting with Gliomatosis-Like Spread, Lack of Contrast Enhancement, EGFR Mutation, and TERT Promoter Variants.
Smith HL et al.
Journal of Neuropathology and Experimental Neurology, 2021
Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
Sun S et al.
Cancer Medicine, 2021
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
Roosan MR et al.
Chest, 2021
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
Robichaux JP et al.
Nature, 2021
A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer Database.
Pappula AL et al.
Cancers, 2021